Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
1. Lyell initiated Phase 3 trial for ronde-cel against established CAR T therapies. 2. Ronde-cel aims to improve response rates in aggressive lymphoma. 3. FDA granted RMAT and Fast Track designations for ronde-cel development. 4. Experts optimistic about ronde-cel's potential based on preliminary results. 5. First patient enrollment expected by early 2026, targeting 400 participants.